On November 3, 2025 CREATE Medicines, Inc. (formerly Myeloid Therapeutics), a clinical-stage biotech pioneering in vivo multi-immune programming, reported that clinical results from its Phase 1 MYE Symphony trial evaluating MT-302 have been accepted for a late-breaking oral presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) (SITC 2025) in National Harbor, Maryland (November 5 – 9, 2025).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"The preliminary clinical results from our Phase 1 trial of MT-302 demonstrate that in vivo immune programming has the potential to overcome the fundamental limitations that have kept CAR therapies confined to blood cancers," said Matt Maurer, Chief Medical Officer of CREATE Medicines. "We believe this approach can create a new treatment paradigm for solid tumors, offering patients systemic, redosable therapies without the complexity and cost barriers of traditional cell therapy."
MT-302 is an investigational mRNA-LNP in vivo CAR therapy designed to elicit an adaptive immune response against solid tumors. Delivered systemically using CREATE’s mRNA-LNP platform, MT-302 programs the immune system to recognize and eliminate TROP2-expressing solid tumors by encoding a TROP2-specific chimeric antigen receptor to selectively reprogram myeloid cells. This approach eliminates the need for ex vivo manipulation or preconditioning, while enabling repeat dosing and tunable CAR expression for potent anti-tumor activity.
Additional details will be presented during the SITC (Free SITC Whitepaper) Annual Meeting and will be available on the SITC (Free SITC Whitepaper) website, View Source, following the embargo lift on November 7, 2025, at 9:00 a.m. ET.
Presentation Details:
Title: First-in-Human Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Initial Efficacy of mRNA-LNP MT-302 In Vivo CAR Therapy in Solid Tumors
Presenting Author: Dr. Rasha Cosman, The Kinghorn Cancer Centre, St. Vincent’s Hospital, Darlinghurst, NSW, Australia
Category: Clinical Oral Abstract Session 1
Abstract Number: LBA 1342
Session Date & Time: Friday, November 7, 2025: 11:30 AM ET- 12:15 PM
Location: Gaylord National Resort & Convention Center, Potomac Ballroom, National Harbor, MD
(Press release, Create Medicines, NOV 3, 2025, View Source [SID1234659305])